INVASION
AND METASTASIS
Malignant disease processes have the ability to allow the spread or
transfer of cancerous cells from one organ or body part to another by invasion
and metastasis. Patterns of metastasis can be partially explained by
circulatory patterns and by specific affinity for cer-tain malignant cells to
bind to molecules in specific body tissue.
Invasion, which refers to the growth of the primary tumor into the
surrounding host tissues, occurs in several ways. Mechanical pressure exerted
by rapidly proliferating neoplasms may force fingerlike projections of tumor
cells into surrounding tissue and interstitial spaces. Malignant cells are less
adherent and may break off from the primary tumor and invade adjacent
structures. Ma-lignant cells are thought to possess or produce specific destructive
enzymes (proteinases), such as collagenases (specific to collagen), plasminogen
activators (specific to plasma), and lysosomal hydro-lyses. These enzymes are
thought to destroy surrounding tissue, in-cluding the structural tissues of the
vascular basement membrane, facilitating invasion of malignant cells. The
mechanical pressure of a rapidly growing tumor may enhance this process.
Metastasis is the dissemination or spread of malignant cells from the primary tumor to distant sites by direct spread of tumor cells to body cavities or through lymphatic and blood circulation. Tumors growing in or penetrating body cavities may shed cells or emboli that travel within the body cavity and seed the surfaces of other organs. This can occur in ovarian cancer when malignant cells enter the peritoneal cavity and seed the peritoneal surfaces of such abdominal organs as the liver or pancreas.
Lymph and blood are key
mechanisms by which cancer cells spread. Angiogenesis, a mechanism by which the
tumor cells are ensured a blood supply, is another important process.
The most common mechanism of metastasis is lymphatic spread, which is
transport of tumor cells through the lymphatic circula-tion. Tumor emboli enter
the lymph channels by way of the inter-stitial fluid that communicates with
lymphatic fluid. Malignant cells also may penetrate lymphatic vessels by
invasion. After en-tering the lymphatic circulation, malignant cells either
lodge in the lymph nodes or pass between lymphatic and venous circulation.
Tumors arising in areas of the body with rapid and extensive lym-phatic
circulation are at high risk for metastasis through lymphatic channels. Breast
tumors frequently metastasize in this manner through axillary, clavicular, and
thoracic lymph channels.
Another metastatic mechanism is hematogenous spread, by which malignant
cells are disseminated through the bloodstream. Hema-togenous spread is
directly related to the vascularity of the tumor. Few malignant cells can
survive the turbulence of arterial circu-lation, insufficient oxygenation, or
destruction by the body’s immune system. In addition, the structure of most
arteries and arterioles is far too secure to permit malignant invasion. Those
malignant cells that do survive this hostile environment are able to attach to
endothelium and attract fibrin, platelets, and clotting factors to seal
themselves from immune system surveillance. The endothelium retracts, allowing
the malignant cells to enter the basement membrane and secrete lysosomal
enzymes. These en-zymes then destroy surrounding body tissues and thereby allow
implantation.
Malignant cells also have the ability to induce the growth of new
capillaries from the host tissue to meet their needs for nutrients and oxygen.
This process is referred to as angiogenesis. It is through this vascular
network that tumor emboli can enter the systemic circu-lation and travel to
distant sites. Large tumor emboli that become trapped in the microcirculation
of distant sites may further metas-tasize to other sites. Research into ways to
prevent angiogenesis is ongoing.
Malignant
transformation, or carcinogenesis,
is thought to be at least a three-step cellular process: initiation, promotion,
and progression.
In initiation, the first step, initiators (carcinogens), such as
chemicals, physical factors, and biologic agents, escape normal enzymatic
mechanisms and alter the genetic structure of the cellular DNA. Normally, these
alterations are reversed by DNA repair mechanisms, or the changes initiate
programmed cellu-lar suicide (apoptosis). Occasionally, cells escape these
protective mechanisms, and permanent cellular mutations occur. These mutations
usually are not significant to cells until the second step of
carcinogenesis.During promotion,
repeated exposure to promoting agents (co-carcinogens) causes the expression of
abnormal or mutant ge-netic information even after long latency periods. Latency
peri-ods for the promotion of cellular mutations vary with the type of agent
and the dosage of the promoter as well as the innate char-acteristics of the
target cell.
Cellular oncogenes, present in all mammalian systems, are responsible
for the vital cellular functions of growth and differ-entiation. Cellular
proto-oncogenes are present in cells and act as an “on switch” for cellular
growth. Similarly, cancer suppres-sor genes “turn off” or regulate unneeded
cellular proliferation. When the suppressor genes become mutated, rearranged,
or am-plified or lose their regulatory capabilities, malignant cells are
allowed to reproduce. The p53 gene is a tumor suppressor gene that is
frequently mutated in many human cancers. This gene reg-ulates whether cells will
repair or die after DNA damage. Mutant p53 gene is associated with a poor
prognosis and may be associated with determining response to treatment. Once
this genetic ex-pression occurs in cells, the cells begin to produce mutant
cell populations that are different from their original cellular ancestors.
Progression is the third step of cellular carcinogenesis. The cel-lular changes
formed during initiation and promotion now exhibit increased malignant
behavior. These cells now show a propensity to invade adjacent tissues and to
metastasize. Agents that initiate or promote cellular transformation are
referred to as carcinogens.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.